modelAtenololAndNifedipine

Diagram of AtenololAndNifedipine

Extends from Pharmacolibrary.Drugs.ATC.C.C07FB03.

Information

name:AtenololAndNifedipine
ATC code:C07FB03
route:
compartments:0
dosage:1mg
volume of distribution:1L
clearance:0
other parameters in model implementation

Combination of atenolol, a selective beta-1 adrenergic blocker, and nifedipine, a dihydropyridine calcium channel blocker. Used for the management of hypertension and angina pectoris. The drug is approved and used in clinical practice today, particularly when single-agent therapy is insufficient.

Pharmacokinetics

No direct pharmacokinetic studies or population PK models published for the fixed dose combination of atenolol and nifedipine (ATC C07FB03) were found. Individual pharmacokinetics for each agent are well-characterized, but specific combination PK parameters are not reported in the literature for healthy or patient populations.

References

  1. Langtry, HD, & Markham, A (1997). Lisinopril. A review of its pharmacology and clinical efficacy in elderly patients. Drugs & aging 10(2) 131–166. DOI:10.2165/00002512-199710020-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9061270

  2. Larochelle, P (1990). Hypertension in the elderly. Cardiovascular drugs and therapy 4 Suppl 5 947–950. DOI:10.1007/BF02018298 PUBMED:https://pubmed.ncbi.nlm.nih.gov/2076405

  3. McTavish, D, et al., & Sorkin, EM (1993). Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 45(2) 232–258. DOI:10.2165/00003495-199345020-00006 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7681374

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)